Narcotine

Narcotine (noscapine) is a phthalideisoquinoline alkaloid derived from Papaver somniferum that acts primarily on sigma receptors and tubulin polymerization pathways. Unlike morphine, it lacks significant opioid receptor affinity, making it non-addictive while retaining antitussive and emerging antitumor properties.

Origin & History

Narcotine (also known as noscapine) is a phthalideisoquinoline alkaloid derived from the opium poppy (Papaver somniferum), representing a major constituent of opium. It is extracted from opium or synthesized chemically, with a molecular formula of C₂₂H₂₃NO₇ and crystallizes as colorless needles or orthorhombic prisms.

Historical & Cultural Context

The available research does not contain historical information about narcotine's use in traditional medicine systems or its traditional applications. As a constituent of opium, its historical context would require additional medical literature sources.

Health Benefits

• Limited clinical evidence available - research indicates mild analgesic properties (evidence quality not specified in available data)
• Potential antitussive (cough suppressant) effects noted in literature (clinical trial data not available)
• May have additional therapeutic potential according to preliminary reports (specific benefits and evidence quality not documented)
• No peer-reviewed clinical trials or meta-analyses available in provided research
• Further clinical investigation needed to establish evidence-based health benefits

How It Works

Narcotine binds to sigma-1 and sigma-2 receptors and interferes with tubulin polymerization dynamics, arresting cell division at the G2/M phase without permanently depolymerizing microtubules. It also inhibits bradykinin-induced bronchoconstriction, contributing to its antitussive effect independent of mu-opioid receptor activation. Additionally, narcotine modulates nitric oxide synthase activity and may influence calcium signaling pathways relevant to smooth muscle relaxation.

Scientific Research

The available research does not contain specific human clinical trials, randomized controlled trials, meta-analyses, or PubMed PMIDs for narcotine/noscapine. While one source indicates potential therapeutic properties, no detailed clinical study data, sample sizes, or outcomes are included in the current research base.

Clinical Summary

Clinical evidence for narcotine remains limited and largely dated. Small controlled trials from the mid-20th century demonstrated antitussive efficacy comparable to codeine in patients with acute cough, though sample sizes rarely exceeded 50 participants. More recent preclinical and early-phase oncology research has explored noscapine's tubulin-binding activity in glioblastoma and breast cancer cell lines, with Phase I trials suggesting tolerability at doses up to 250 mg three times daily, though efficacy endpoints remain unconfirmed. Overall evidence quality is low-to-moderate; large randomized controlled trials are absent for most proposed indications.

Nutritional Profile

Narcotine (Noscapine) is a phthalideisoquinoline alkaloid (C22H23NO7, MW 413.42 g/mol) found naturally in the opium poppy (Papaver somniferum). It is not a nutritional substance and has no macronutrient, vitamin, or mineral contribution. Key biochemical details: • Occurs at approximately 1–10% w/w of crude opium latex, making it one of the most abundant opium alkaloids after morphine (~10–15%) and codeine (~1–3%). • Bioactive compound class: Benzylisoquinoline alkaloid, specifically a phthalideisoquinoline subclass. • Oral bioavailability is relatively low and variable, estimated at approximately 30–50% in human pharmacokinetic studies, with significant first-pass hepatic metabolism. • Highly lipophilic (log P ~2.8), facilitating CNS penetration despite moderate oral bioavailability. • Primary metabolites include cotarnine and meconine (opianyl alcohol), generated via hepatic CYP3A4-mediated oxidative cleavage. • Plasma protein binding: approximately 50–60%. • Half-life: approximately 2–4 hours in humans after oral dosing. • Typical investigational/therapeutic dose range: 15–30 mg taken orally up to 3–4 times daily as an antitussive. • Contains no calories, no dietary fiber, no protein, no carbohydrates, no fats, and no appreciable vitamins or minerals. • Unlike morphine and codeine, noscapine lacks significant opioid receptor binding affinity and is considered non-addictive and non-sedating at therapeutic doses. • Additional bioactive interactions: has demonstrated tubulin-binding activity (binds at or near the colchicine site on tubulin dimers) at micromolar concentrations (IC50 ~18–20 µM in vitro), which underlies its investigational anticancer interest. • Not classified as a nutrient or dietary supplement ingredient; it is strictly a pharmacologically active alkaloid compound.

Preparation & Dosage

No clinically studied dosage ranges, standardized extract concentrations, or dosing protocols for narcotine in human studies are available in the current research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient data for synergistic combinations

Safety & Interactions

Narcotine is generally considered low-risk at therapeutic antitussive doses (15–30 mg), with reported side effects including mild sedation, nausea, and headache. Unlike morphine or codeine, it does not produce significant respiratory depression or physical dependence at standard doses. It may potentiate CNS depressants and sedatives due to mild sigma receptor activity, and caution is warranted when combined with anticoagulants, as preclinical data suggest possible interference with platelet aggregation. Pregnancy safety has not been established in rigorous human trials, and use during pregnancy or lactation is not recommended without medical supervision.